pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma
Ningbo Cancer Hospital
Ningbo Cancer Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carci
Company details
- Status
- Public
- HQ
- CN
- Programs
- 120
- Drugs
- 183
- Patents
- 0
UC-BCG-2409/BIG 2402
Phase 3 · small molecule · Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.
UC-BCG-2409/BIG 2402 for Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm. is a Phase 3 program (small_molecule) at Ningbo Cancer Hospital with 1 ClinicalTrials.gov record(s).
Internal code UC-BCG-2409/BIG 2402
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ningbo Cancer Hospital
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.
- Status
- active
- Trials
- 1